Group
Residual Tumor and Response to Treatment (RT2Lab)
Department :
Translational Research Department
Presentation
Neoadjuvant treatment (i.e treatment before surgery) represents an opportunity to study and monitor “in vivo” treatment-sensitivity of the tumor. It enables leveraging the potential of clinical research in breast cancer and represents per se the optimal framework for translational research. By applying strategies inspired from radiotherapy, immunotherapy, genetics and epigenetics etc… a wide variety of treatments can be evaluated and monitored.
Neoadjuvant treatment (i.e treatment before surgery) represents an opportunity to study and monitor “in vivo” treatment-sensitivity of the tumor. It enables leveraging the potential of clinical research in breast cancer and represents per se the optimal framework for translational research. By applying strategies inspired from radiotherapy, immunotherapy, genetics and epigenetics etc… a wide variety of treatments can be evaluated and monitored. Neoadjuvant setting involves multiple fields of clinical research (drugs investigation / imaging / circulating biomarkers etc…) and provides multiple opportunities for early assessment/ dynamic evaluation of biomarkers / as well as possible iterative tumor sampling throughout treatment course. This model is the appropriate tool to draw a comprehensive analysis of mechanisms of resistance to treatment by analyzing residual tumor.
The core research field of the RT2Lab is to take advantage of the neoadjuvant window to explore sensitivity or resistance to treatment using mixed multimodal datas.
Several other projects in the breast cancer field are also studied (see below).
The github of the lab can be found at the following address:
